Diagnostic and Testing Equipment M&A update, 14–28 September 2026
A bi-weekly read on Diagnostic and Testing Equipment covering public-market movers, major company announcements, and M&A activity for September 14–28, 2026. Built for owners, acquirers and advisors tracking valuation, deal multiples and the recurring-revenue theme shaping the space.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Diagnostic and Testing Equipment Sector Outlook — September 2026
Key figures
- Covered-set median move
- +3.8%
- 25 names, close-to-close
- Illumina (ILMN) move
- +30.6%
- Sep 14–28, 2026
- Precedent deal multiple
- 8.8x
- EV/LTM EBITDA, 40 recorded deals
- Sector valuation
- 21.1x
- CY2027E EV/EBITDA
Read the report
1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT
Executive summary
Across September 14–28, 2026, 18 of 25 covered names rose and the median move was +3.8%, ahead of the S&P 500's +0.8%. Illumina led gainers at +30.6% on a growth and outlook story, while the period's one agreed transaction — IDEXX's acquisition of CoVet — adds to a trailing record of 40 precedent deals at a median 8.8x EV/EBITDA. The evidence points toward recurring, workflow-adjacent assets earning the stronger market response this period.
Key findings
- 18 of 25 covered names rose; median move was +3.8%, beating the S&P 500's +0.8%
- Illumina led at +30.6%, tied to a raised 2026 outlook and sequencing growth
- IDEXX's CoVet deal was the period's only agreed transaction, against 8.8x median comps
- Sector trades at 21.1x CY2027E EV/EBITDA; Premium tier 48.5x, Discount tier 9.0x
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT
Cover slide identifying the report as a bi-weekly industry events and M&A update for Diagnostic and Testing Equipment, September 14–28, 2026.
This is our bi-weekly read on Diagnostic and Testing Equipment for September 14–28, 2026. We'll walk through what changed, who moved and most likely why, what transacted, and what it means for the people who act on it.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT Consumable Annuities Earn the Bid While Placement Stories Wait This update covers the two-week period September 14–28, 2026 in diagnostic and testing equipment: who moved, what companies announced, and the one agreed transaction. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Buyers Reward the Recurring Side of the Menu
The bottom-line page shows that 18 of 25 covered names rose, with a median move of +3.8% against the S&P 500's +0.8%.
Across the 25 names we cover, 18 rose and the median move was +3.8%, comfortably ahead of the S&P 500's +0.8% over the same window. This was a broad move, not one driven by a single name. Illumina led the group and the period's one agreed transaction, IDEXX's acquisition of CoVet, added to a deal record priced at a median 8.8x EV/EBITDA. So what: the period's evidence favors recurring, workflow-adjacent business over one-off placement stories.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Buyers Reward the Recurring Side of the Menu The two-week period in one page · 25 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 18 of 25 Covered Names Rose; The Median Move Was +3.8% The set ran ahead of the S&P 500, which returned +0.8% over the window. Direction was broad rather than driven by one or two names. 2 Illumina Led the Set on a Growth and Outlook Story Illumina, Inc. (ILMN) rose +30.6%, with its biggest single day of +7.3% on Sep 24. Coverage that day tied a 94.9% year-to-date rally to sequencing growth, clinical adoption and a raised 2026 outlook. 3 The Period's One Agreed Deal Bought Workflow Around an Installed Base IDEXX Laboratories, Inc. (IDXX) announced the acquisition of CoVet, adding veterinary workflow intelligence. The trailing record carries 40 precedent transactions at a median of 8.8x EV/EBITDA. 4 The Window Sits Comfortably with the Standing View of the Sector NeuraCap's standing lens marks the sector at 21.1x CY2027E EV/EBITDA, with the Premium tier at a 48.5x median and the Discount tier at 9.0x. Repligen Corporation (RGEN), a Premium-tier name, was among the period's largest gainers. +30.6% Best mover — Illumina, Inc. (ILMN) worst: SSII -14.7% · 18 up / 7 down of 25 covered +3.8% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution
- 03PUBLIC MARKET MOVERS
One Mover with a Stated Story, and Three the Record Does Not Explain
The public market movers page identifies Illumina's stated growth story and flags three other movers the recorded evidence does not explain.
Illumina rose +30.6% over the window, including a +7.3% single-day move on September 24 tied by coverage that day to a 94.9% year-to-date rally, sequencing growth, clinical adoption and a raised 2026 outlook. Against a sector median of +3.8% and a materiality bar of ±9.4%, that move stands out with a stated driver on record. Other moves in the set cross the materiality bar without a recorded filing or headline attached. So what: we anchor conviction to the moves with a documented cause and treat the rest as open questions for follow-up.
Everything on this page
PUBLIC MARKET MOVERS One Mover with a Stated Story, and Three the Record Does Not Explain Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +3.8% · S&P 500 +0.8% · materiality bar ±9.4% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +3.8% Illumina, Inc. (ILMN) +30.6% The move appears to reflect the growth story set out in Sep 24 coverage of the company's 94.9% year-to-date rally: sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds. Menu breadth and clinical adoption on a placed platform still set the mark for the sector's growth names. COMPANY-SPECIFIC OraSure Technologies, Inc. (OSUR) +17.2% No notable in-window news was identified that clearly explains the move. At +17.2%, OraSure Technologies, Inc. (OSUR) ran ahead of the set's +3.8% median. Where the company record is quiet, the set's median is the only clean reference point. UNEXPLAINED Repligen Corporation (RGEN) +15.5% No notable in-window news was identified that clearly explains the move. The +15.5% gain was well above the set's +3.8% median. Repligen is a Premium-tier name, and the consumables side of this sector carries the higher mark. UNEXPLAINED SS Innovations International, Inc. (SSII) -14.7% No notable in-window news was identified that clearly explains the move. At -14.7%, SS Innovations International, Inc. (SSII) sat furthest from the set's +3.8% median. Placement-led device stories move on their own timetable, with little help from the set's direction. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
What Companies Actually Did: Menu, Partnerships and a Settled Claim
This page lists the highest-impact company announcements of the period, including new menu items, partnerships and a settled claim.
The two weeks brought concrete product and partnership moves rather than only market chatter. Waters stood behind an FDA-cleared at-home HPV screening tool with Everlywell and launched its A7 analyzer, while Senseonics moved to integrate Eversense 365 with the iLet Bionic Pancreas. Each item here links back to its underlying filing or article, and our "why it matters" read is offered as our own interpretation, not the last word. So what: these are the announcements most likely to shape competitive position over the next quarter.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Menu, Partnerships and a Settled Claim The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 16 · NEWS · Business Wire IDEXX acquires CoVetAI to advance veterinary workflow intelligence Veterinary is one of the sector's more defensible non-clinical annuities, and a Core-tier name is buying workflow rather than menu. Informatics attached to an installed base is being bought, not built. Sep 16 · NEWS · GlobeNewsWire Philips-led projects win ITEA awards for AI-enabled healthcare work Recognition for connected healthcare ecosystems and fiber-optic sensing shows where Koninklijke Philips N.V. (PHG) is putting development effort. Workflow and informatics integration is where installed-base defence gets built. Sep 16 · NEWS · Business Wire Everlywell partners with Waters on an FDA-cleared at-home HPV screening tool This is testing moving out of the central lab toward the home, with a cleared tool behind it. For Waters Corporation (WAT), a Core-tier name, home collection widens the volume a placed platform can pull through. At-home collection extends the central-lab menu rather than replacing it. Sep 15 · NEWS · Business Wire Neogen sets its first-quarter earnings release date for October 6 This is timing rather than news about the business: it fixes when the next operating read from Neogen Corporation (NEOG), a Core-tier name, reaches the market. The next scheduled report gives the set a check on recurring revenue quality. Sep 14 · NEWS · GlobeNewsWire Senseonics partners with Beta Bionics to integrate Eversense 365 with the iLet pump Pairing a year-long continuous glucose sensor with automated insulin delivery is a workflow move aimed at an existing user community. The NeuraCap read: in this sector, integration arrangements often precede ownership. Distribution and integration deals are the usual first step toward a transaction. Sep 14 · NEWS · PRNewsWire Waters launches the BD FACSDiscover A7 cell analyzer for spectral flow cytometry A commercial launch is a placement event with a consumable and service stream behind it, and standardised instrument-to-instrument performance is what lowers a lab's objection to switching. Launch cadence on one platform is how menu expansion shows up in revenue.
- 05M&A & STRATEGIC ACTIVITY
IDEXX Buys the Workflow Layer Sitting Around Its Veterinary Base
The M&A page covers the one agreed transaction of the period, IDEXX's acquisition of CoVet, against a backdrop of 40 precedent deals.
IDEXX Laboratories announced the acquisition of CoVet, adding veterinary workflow intelligence around its installed base. That single agreed deal joins a trailing record of 40 precedent transactions priced at a median 8.8x EV/LTM EBITDA where disclosed. We read the logic as IDEXX buying the workflow layer that sits around its existing veterinary footprint rather than new placement volume. So what: the multiple discipline in the precedent set gives buyers and targets a real reference point for the next deal in this space.
Everything on this page
M&A & STRATEGIC ACTIVITY IDEXX Buys the Workflow Layer Sitting Around Its Veterinary Base September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals · median 8.8x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 17 · IDEXX Laboratories, Inc. (IDXX) IDEXX Laboratories (IDXX) acquires CoVet, adding workflow intelligence to its veterinary business The period's one announced transaction has a strategic buying software around a base it already serves. The NeuraCap read: appetite is pointing at recurring, non-clinical end markets rather than pre-reimbursement clinical assets. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against 8.8x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed
- 06WHAT IT MEANS
Where the Period Leaves Owners, Buyers and Advisors
This page translates the period's evidence into implications for owners, acquirers and advisors.
For owners and operators, the market is already rewarding recurring mix: 18 of 25 covered names rose and the median move of +3.8% beat the S&P 500's +0.8%. For acquirers, the period adds one new data point, IDEXX's CoVet deal, to a reference set of 40 precedent transactions at a median 8.8x EV/EBITDA. For advisors, the pattern across IDEXX, Waters and Senseonics points toward leading with the annuity story rather than the placement year. So what: each audience has a specific, evidence-based cue to act on from this window alone.
Everything on this page
WHAT IT MEANS Where the Period Leaves Owners, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 21.1x 26 companies in the study 3 valuation tiers Standing thesis: Diagnostic and testing equipment prices consumables annuities apart from placement-led devices FOR OWNERS & OPERATORS Recurring Mix Is Doing the Work Companies in the space traded higher: 18 of 25 covered names rose and the median move was +3.8%, against +0.8% for the S&P 500. FOR ACQUIRERS One New Record, and a Reference Set That Moved Up The period adds one announced transaction, IDEXX Laboratories' acquisition of CoVet, to a trailing record of 40 precedent transactions at a median of 8.8x EV/EBITDA. FOR ADVISORS Lead with the Annuity, Not the Placement Year The period's evidence runs one way: IDEXX buying veterinary workflow, Waters behind an FDA-cleared at-home HPV screening tool with Everlywell and launching the A7 analyzer, and Senseonics integrating Eversense 365 with the iLet Bionic Pancreas.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
The closing page explains the sources and methodology behind every figure and driver attribution in the update.
Every figure in this update links back to the filing, press release or established outlet it was drawn from, in a fixed reliability order. Driver attributions use calibrated language and reflect our read of the recorded evidence, not asserted causation. So what: readers can trace any number or claim in this deck back to its underlying source before acting on it.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T154913Z_524_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com · prnewswire.com · sec.gov
Sources and methodology
This update covers Diagnostic and Testing Equipment over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 25 listed companies whose core business is Diagnostic and Testing Equipment under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Abbott Laboratories (ABT), Bio-Rad Laboratories, Inc. (BIO), Carlsmed, Inc. (CARL), CeriBell, Inc. (CBLL), CapsoVision, Inc. (CV), DexCom, Inc. (DXCM), IDEXX Laboratories, Inc. (IDXX), Illumina, Inc. (ILMN), Inspire Medical Systems, Inc. (INSP), IRadimed Corporation (IRMD), KORU Medical Systems, Inc. (KRMD), Lucid Diagnostics Inc. (LUCD), Mesa Laboratories, Inc. (MLAB), Maravai LifeSciences Holdings, Inc. (MRVI), MaxCyte, Inc. (MXCT), Nautilus Biotechnology, Inc. (NAUT), Neogen Corporation (NEOG), Anbio Biotechnology Class A Ordinary Shares (NNNN), OraSure Technologies, Inc. (OSUR), Koninklijke Philips N.V. (PHG), Repligen Corporation (RGEN), Senseonics Holdings, Inc. (SENS), SS Innovations International, Inc. (SSII), Waters Corporation (WAT), Exagen Inc. (XGN). 1 name below the floor was excluded from the statistics: DXR.
Window and company universe
This update covers Diagnostic and Testing Equipment over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 25 listed companies whose core business is Diagnostic and Testing Equipment under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Abbott Laboratories (ABT), Bio-Rad Laboratories, Inc. (BIO), Carlsmed, Inc. (CARL), CeriBell, Inc. (CBLL), CapsoVision, Inc. (CV), DexCom, Inc. (DXCM), IDEXX Laboratories, Inc. (IDXX), Illumina, Inc. (ILMN), Inspire Medical Systems, Inc. (INSP), IRadimed Corporation (IRMD), KORU Medical Systems, Inc. (KRMD), Lucid Diagnostics Inc. (LUCD), Mesa Laboratories, Inc. (MLAB), Maravai LifeSciences Holdings, Inc. (MRVI), MaxCyte, Inc. (MXCT), Nautilus Biotechnology, Inc. (NAUT), Neogen Corporation (NEOG), Anbio Biotechnology Class A Ordinary Shares (NNNN), OraSure Technologies, Inc. (OSUR), Koninklijke Philips N.V. (PHG), Repligen Corporation (RGEN), Senseonics Holdings, Inc. (SENS), SS Innovations International, Inc. (SSII), Waters Corporation (WAT), Exagen Inc. (XGN). 1 name below the floor was excluded from the statistics: DXR.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +30.6% (investorplace.com)
- +17.2% (defenseworld.net)
- +15.5% (sec.gov)
- IDEXX acquires CoVetAI to advance veterinary workflow intelligence (businesswire.com)
- Philips-led projects win ITEA awards for AI-enabled healthcare work (globenewswire.com)
- Everlywell partners with Waters on an FDA-cleared at-home HPV screening (businesswire.com)
- Neogen sets its first-quarter earnings release date for October 6 (businesswire.com)
- Senseonics partners with Beta Bionics to integrate Eversense 365 with the (globenewswire.com)
- Waters launches the BD FACSDiscover A7 cell analyzer for spectral flow (prnewswire.com)
- IDEXX Laboratories (IDXX) acquires CoVet, adding workflow intelligence to its veterinary (zacks.com)
- prnewswire.com (prnewswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Diagnostic and Testing Equipment Sector Outlook — September 2026
- M&A Update · 29 September 2026Digital Health and Telehealth M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Digital Health and Telehealth Sector Outlook — September 2026
- M&A Update · 29 September 2026Generic and Non-Prescription Drugs M&A update, 14–28 September 2026
Want this analysis for a company in Diagnostic and Testing Equipment?
Company valuation reports run the same method against a single business — public or private.
